SCHEMBL5651004

SCHEMBL5651004

CCN(CC)CCCNC(=O)c1ccc(-c2nc3cccc(C)c3[nH]2)c(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
IGF1R P08069 2/20 0.40
KDM4E B2RXH2 2/20 0.40
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
GLA P06280 1/20 0.40
HSD17B10 Q99714 1/20 0.40
USP7 Q93009 2/20 0.40
TMEM97 Q5BJF2 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
NSD2 O96028 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650419 0.92 TP53 (0.46) TP53GAAHTTSMN1; SMN2KDM4E
SCHEMBL5650434 0.87 FLT3 (0.47) KDM4EHSD17B10
SCHEMBL5654556 0.87 PRMT5 (0.42) TP53GAAHTTSMN1; SMN2IGF1R
SCHEMBL5649820 0.86 GAA (0.45) TP53GAAHTTSMN1; SMN2IGF1R
SCHEMBL5650993 0.86 HPSE (0.49) TP53GAAHTTSMN1; SMN2IGF1R
SCHEMBL5649064 0.85 HDAC6 (0.46) TP53GAAHTTSMN1; SMN2MAPT
SCHEMBL5651909 0.85 TP53 (0.45) TP53GAAHTTSMN1; SMN2KDM4E
SCHEMBL5650314 0.83 HDAC6 (0.47) TP53GAAHTTSMN1; SMN2KDM4E
SCHEMBL5651973 0.82 HTT (0.47) TP53GAAHTTSMN1; SMN2KDM4E
SCHEMBL5651963 0.82 HTT (0.47) TP53GAAHTTSMN1; SMN2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 TP53 4051/4885GAA 4139/4885HTT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.